It may be rational for the physicians to monitor these drugs frequently, even if monitoring is not needed, to make sure that the patient is compliant.

The author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed ...

A dedicated FAQ section is available for common drugs to address questions and provide a deeper understanding of Anticoagulants management options. Remember to consult your healthcare provider for ...

A new class of anticoagulant drugs on the horizon is taking fresh aim at one of cardiology’s toughest challenges: how to prevent blood clots that cause heart attacks and strokes, without leaving ...

Investigators believe that this new anticoagulant, named tecarfarin ... making it susceptible to drug–drug and drug–food interactions, and meaning that it produces highly variable clinical ...

A pair of Regeneron’s monoclonal antibodies have held their own against a commonly used anticoagulant in a phase 2 trial, ...

Regeneron (NASDAQ:REGN) reported positive Phase 2 data for its thrombosis drug candidates REGN7508 and REGN9933 and plans to ...

They found this true for antihypertensives, lipid-lowering drugs, oral anticoagulants, and diuretics. However, they found that short-term use of 1 to 4 years of all cardiovascular medication ...

The company is planning a “broad Phase 3 program” for two anticoagulants after they outperformed marketed medicines in a pair ...

These drugs included: Combining antihypertensives with lipid-lowering medications, diuretics, or oral anticoagulants for 5 years or more was also associated with a reduced risk. In contrast ...